Prediction of fetal ductus arteriosus constriction by systemic and local dermatological formulations of NSAIDs based on PK/PD analysis

Shingo Tanaka, Satoko Hori, Hiroki Satoh, Yasufumi Sawada

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aim: Use of nonsteroidal anti-inflammatory drugs (NSAIDs) during the final trimester of pregnancy can cause fetal toxicity, such as ductus arteriosus (DA) constriction. The aim of this study was to predict quantitatively the fetal DA-constrictive effects of NSAIDs after various routes of administration to the mother by means of pharmacokinetic/pharmacodynamic (PK/PD) modeling. Methods: We evaluated acetaminophen, which is a first-line analgesic/antipyretic for the third trimester of pregnancy, together with the following NSAIDs: indometacin, diclofenac, ibuprofen, flurbiprofen, ketoprofen, loxoprofen, felbinac, naproxen, and celecoxib. Drug concentration data obtained in rats and humans were collected from the literature to calculate PK parameters. Next, the PD parameters for DA constriction in rats were obtained by fitting an Emax model to the DA/pulmonary artery (PA) inner diameter ratio after oral administration of each drug to full-term pregnant rats (data taken from the literature) and the unbound plasma concentration in rat dams estimated from the obtained PK parameters. Finally, the inner DA diameter profile after administration of each drug to human mothers was predicted. Results: This PK/PD model predicted continuous fetal DA constriction in third-trimester women after repeated systemic use of nearly all the NSAIDs evaluated. Local dermatological formulations of NSAIDs were also predicted to potentially cause DA constriction. Conclusion: These results suggest that risk to the fetus should be carefully considered before administration of NSAIDs (especially systemic formulations, but including dermatological formulations) to women in the third trimester of pregnancy.

Original languageEnglish
Pages (from-to)782-794
Number of pages13
JournalInternational Journal of Clinical Pharmacology and Therapeutics
Volume54
Issue number10
DOIs
Publication statusPublished - 2016 Oct 1
Externally publishedYes

Fingerprint

Ductus Arteriosus
Constriction
Anti-Inflammatory Agents
Pharmacokinetics
Pharmaceutical Preparations
Third Pregnancy Trimester
Celecoxib
Mothers
Pregnancy Trimesters
Flurbiprofen
Ketoprofen
Antipyretics
Naproxen
Diclofenac
Ibuprofen
Acetaminophen
Indomethacin
Pulmonary Artery
Oral Administration
Analgesics

Keywords

  • Fetal toxicity
  • Local dermatological formulation
  • Nonsteroidal anti-inflammatory drug
  • PK/PD analysis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Prediction of fetal ductus arteriosus constriction by systemic and local dermatological formulations of NSAIDs based on PK/PD analysis. / Tanaka, Shingo; Hori, Satoko; Satoh, Hiroki; Sawada, Yasufumi.

In: International Journal of Clinical Pharmacology and Therapeutics, Vol. 54, No. 10, 01.10.2016, p. 782-794.

Research output: Contribution to journalArticle

@article{f4e2627ef4d04ca8a4efdf88b8e1328e,
title = "Prediction of fetal ductus arteriosus constriction by systemic and local dermatological formulations of NSAIDs based on PK/PD analysis",
abstract = "Aim: Use of nonsteroidal anti-inflammatory drugs (NSAIDs) during the final trimester of pregnancy can cause fetal toxicity, such as ductus arteriosus (DA) constriction. The aim of this study was to predict quantitatively the fetal DA-constrictive effects of NSAIDs after various routes of administration to the mother by means of pharmacokinetic/pharmacodynamic (PK/PD) modeling. Methods: We evaluated acetaminophen, which is a first-line analgesic/antipyretic for the third trimester of pregnancy, together with the following NSAIDs: indometacin, diclofenac, ibuprofen, flurbiprofen, ketoprofen, loxoprofen, felbinac, naproxen, and celecoxib. Drug concentration data obtained in rats and humans were collected from the literature to calculate PK parameters. Next, the PD parameters for DA constriction in rats were obtained by fitting an Emax model to the DA/pulmonary artery (PA) inner diameter ratio after oral administration of each drug to full-term pregnant rats (data taken from the literature) and the unbound plasma concentration in rat dams estimated from the obtained PK parameters. Finally, the inner DA diameter profile after administration of each drug to human mothers was predicted. Results: This PK/PD model predicted continuous fetal DA constriction in third-trimester women after repeated systemic use of nearly all the NSAIDs evaluated. Local dermatological formulations of NSAIDs were also predicted to potentially cause DA constriction. Conclusion: These results suggest that risk to the fetus should be carefully considered before administration of NSAIDs (especially systemic formulations, but including dermatological formulations) to women in the third trimester of pregnancy.",
keywords = "Fetal toxicity, Local dermatological formulation, Nonsteroidal anti-inflammatory drug, PK/PD analysis",
author = "Shingo Tanaka and Satoko Hori and Hiroki Satoh and Yasufumi Sawada",
year = "2016",
month = "10",
day = "1",
doi = "10.5414/CP202532",
language = "English",
volume = "54",
pages = "782--794",
journal = "International Journal of Clinical Pharmacology and Therapeutics",
issn = "0946-1965",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "10",

}

TY - JOUR

T1 - Prediction of fetal ductus arteriosus constriction by systemic and local dermatological formulations of NSAIDs based on PK/PD analysis

AU - Tanaka, Shingo

AU - Hori, Satoko

AU - Satoh, Hiroki

AU - Sawada, Yasufumi

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Aim: Use of nonsteroidal anti-inflammatory drugs (NSAIDs) during the final trimester of pregnancy can cause fetal toxicity, such as ductus arteriosus (DA) constriction. The aim of this study was to predict quantitatively the fetal DA-constrictive effects of NSAIDs after various routes of administration to the mother by means of pharmacokinetic/pharmacodynamic (PK/PD) modeling. Methods: We evaluated acetaminophen, which is a first-line analgesic/antipyretic for the third trimester of pregnancy, together with the following NSAIDs: indometacin, diclofenac, ibuprofen, flurbiprofen, ketoprofen, loxoprofen, felbinac, naproxen, and celecoxib. Drug concentration data obtained in rats and humans were collected from the literature to calculate PK parameters. Next, the PD parameters for DA constriction in rats were obtained by fitting an Emax model to the DA/pulmonary artery (PA) inner diameter ratio after oral administration of each drug to full-term pregnant rats (data taken from the literature) and the unbound plasma concentration in rat dams estimated from the obtained PK parameters. Finally, the inner DA diameter profile after administration of each drug to human mothers was predicted. Results: This PK/PD model predicted continuous fetal DA constriction in third-trimester women after repeated systemic use of nearly all the NSAIDs evaluated. Local dermatological formulations of NSAIDs were also predicted to potentially cause DA constriction. Conclusion: These results suggest that risk to the fetus should be carefully considered before administration of NSAIDs (especially systemic formulations, but including dermatological formulations) to women in the third trimester of pregnancy.

AB - Aim: Use of nonsteroidal anti-inflammatory drugs (NSAIDs) during the final trimester of pregnancy can cause fetal toxicity, such as ductus arteriosus (DA) constriction. The aim of this study was to predict quantitatively the fetal DA-constrictive effects of NSAIDs after various routes of administration to the mother by means of pharmacokinetic/pharmacodynamic (PK/PD) modeling. Methods: We evaluated acetaminophen, which is a first-line analgesic/antipyretic for the third trimester of pregnancy, together with the following NSAIDs: indometacin, diclofenac, ibuprofen, flurbiprofen, ketoprofen, loxoprofen, felbinac, naproxen, and celecoxib. Drug concentration data obtained in rats and humans were collected from the literature to calculate PK parameters. Next, the PD parameters for DA constriction in rats were obtained by fitting an Emax model to the DA/pulmonary artery (PA) inner diameter ratio after oral administration of each drug to full-term pregnant rats (data taken from the literature) and the unbound plasma concentration in rat dams estimated from the obtained PK parameters. Finally, the inner DA diameter profile after administration of each drug to human mothers was predicted. Results: This PK/PD model predicted continuous fetal DA constriction in third-trimester women after repeated systemic use of nearly all the NSAIDs evaluated. Local dermatological formulations of NSAIDs were also predicted to potentially cause DA constriction. Conclusion: These results suggest that risk to the fetus should be carefully considered before administration of NSAIDs (especially systemic formulations, but including dermatological formulations) to women in the third trimester of pregnancy.

KW - Fetal toxicity

KW - Local dermatological formulation

KW - Nonsteroidal anti-inflammatory drug

KW - PK/PD analysis

UR - http://www.scopus.com/inward/record.url?scp=84990050101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990050101&partnerID=8YFLogxK

U2 - 10.5414/CP202532

DO - 10.5414/CP202532

M3 - Article

C2 - 27285464

AN - SCOPUS:84990050101

VL - 54

SP - 782

EP - 794

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

SN - 0946-1965

IS - 10

ER -